Terms: = Ovarian cancer AND PDGFRA, MGC74795, 5156, ENSG00000134853, PDGFR2, CD140A, Rhe-PDGFRA, CD140a, P16234
23 results:
1. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Dvořák J; Němejcová K; Matěj R; Laco J; Drozenová J; Fabian P; Hausnerová J; Méhes G; Škapa P; Švajdler M; Cibula D; Frühauf F; Bártů MK; Dundr P
Diagn Pathol; 2023 Jun; 18(1):72. PubMed ID: 37303048
[TBL] [Abstract] [Full Text] [Related]
2. Diffuse Pediatric-type High-grade Glioma Arising in an ovarian Mature Cystic Teratoma.
Elmuti L; Amundson J; Oberman E; Kamat A; Sedig L; Lastra RR; Aldape K; Quezado M; Pratt DW; Cimino PJ; Abdullaev Z; Pytel P; Applebaum MA; Bennett JA
Int J Gynecol Pathol; 2024 Jan; 43(1):90-96. PubMed ID: 37046379
[TBL] [Abstract] [Full Text] [Related]
3. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
4. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
5. Integrative network analysis identifies potential targets and drugs for ovarian cancer.
Zhang T; Zhang L; Li F
BMC Med Genomics; 2020 Sep; 13(Suppl 9):132. PubMed ID: 32958005
[TBL] [Abstract] [Full Text] [Related]
6. Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA‑Meg3/miR‑421/pdgfra axis.
Ye W; Ni Z; Yicheng S; Pan H; Huang Y; Xiong Y; Liu T
Int J Oncol; 2019 Dec; 55(6):1296-1312. PubMed ID: 31638182
[TBL] [Abstract] [Full Text] [Related]
7. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts.
Liu Y; Chanana P; Davila JI; Hou X; Zanfagnin V; McGehee CD; Goode EL; Polley EC; Haluska P; Weroha SJ; Wang C
Sci Rep; 2019 Apr; 9(1):6314. PubMed ID: 31004097
[TBL] [Abstract] [Full Text] [Related]
8. Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma.
Pozzati F; Moro F; Pasciuto T; Gallo C; Ciccarone F; Franchi D; Mancari R; Giunchi S; Timmerman D; Landolfo C; Epstein E; Chiappa V; Fischerova D; Fruscio R; Zannoni GF; Valentin L; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2018 Dec; 52(6):792-800. PubMed ID: 29978567
[TBL] [Abstract] [Full Text] [Related]
9. Mutational Aberrations Detected in Mucinous Epithelial ovarian cancer of Asian Women.
Chay WY; Kwok LL; Tiong WN; Krisna SS; Lim KH; Iyer NG; Goh LK; Tan DS
Int J Gynecol Cancer; 2018 Mar; 28(3):428-436. PubMed ID: 29465505
[TBL] [Abstract] [Full Text] [Related]
10. Familial Gastrointestinal Stromal Tumor with Germline
Sekido Y; Ohigashi S; Takahashi T; Hayashi N; Suzuki K; Hirota S
Anticancer Res; 2017 Mar; 37(3):1425-1431. PubMed ID: 28314314
[TBL] [Abstract] [Full Text] [Related]
11. Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays.
Holzer TR; O'Neill Reising L; Credille KM; Schade AE; Oakley GJ
J Histochem Cytochem; 2016 Dec; 64(12):785-810. PubMed ID: 27837159
[TBL] [Abstract] [Full Text] [Related]
12. Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ß-D-Digitoxosyl-Mithramycin SK (EC-8042).
Fernández-Guizán A; López-Soto A; Acebes-Huerta A; Huergo-Zapico L; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S
PLoS One; 2015; 10(11):e0140786. PubMed ID: 26536461
[TBL] [Abstract] [Full Text] [Related]
13. miR-140-5p inhibits ovarian cancer growth partially by repression of pdgfra.
Lan H; Chen W; He G; Yang S
Biomed Pharmacother; 2015 Oct; 75():117-22. PubMed ID: 26297547
[TBL] [Abstract] [Full Text] [Related]
14. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
[TBL] [Abstract] [Full Text] [Related]
15. Connecting prognostic ligand receptor signaling loops in advanced ovarian cancer.
Eng KH; Ruggeri C
PLoS One; 2014; 9(9):e107193. PubMed ID: 25244152
[TBL] [Abstract] [Full Text] [Related]
16. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract] [Full Text] [Related]
17. Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.
Skirnisdottir I; Mayrhofer M; Rydåker M; Akerud H; Isaksson A
BMC Cancer; 2012 Sep; 12():407. PubMed ID: 22967087
[TBL] [Abstract] [Full Text] [Related]
18. Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas.
Hersmus R; Stoop H; van de Geijn GJ; Eini R; Biermann K; Oosterhuis JW; Dhooge C; Schneider DT; Meijssen IC; Dinjens WN; Dubbink HJ; Drop SL; Looijenga LH
PLoS One; 2012; 7(8):e43952. PubMed ID: 22937135
[TBL] [Abstract] [Full Text] [Related]
19. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.
Merritt MA; Parsons PG; Newton TR; Martyn AC; Webb PM; Green AC; Papadimos DJ; Boyle GM
BMC Cancer; 2009 Oct; 9():378. PubMed ID: 19849863
[TBL] [Abstract] [Full Text] [Related]
20. Genetic alterations and protein expression of KIT and pdgfra in serous ovarian carcinoma.
Lassus H; Sihto H; Leminen A; Nordling S; Joensuu H; Nupponen NN; Butzow R
Br J Cancer; 2004 Dec; 91(12):2048-55. PubMed ID: 15583695
[TBL] [Abstract] [Full Text] [Related]
[Next]
